Skip to content
Twist Bioscience Corporation logo

Twist Bioscience Corporation

TWST

Twist Bioscience is a life sciences company that has developed a proprietary silicon-based DNA synthesis platform to industrialize the engineering of biology.

Market cap
$5.39B+159%
Revenue$409.5M+17.8%
Net income-$81.3M+57.5%
Free cash flow-$95.0M-45.1%
EPS (diluted)-$1.33+59.1%
Trailing twelve months · change vs. prior year

Earnings

Next report

Aug 3, 2026 (In 5 days)
Revenue estimate$114.5M
EPS estimate-$0.50

Financials

Q2 2026

Income statement

See full
Revenue$110.7M+19.3%
Gross profit$57.1M+24.1%
Operating income-$45.9M-10.4%
Net income-$44.0M-11.9%
EPS (diluted)-$0.71-7.6%

Balance sheet

See full
Cash & equivalents$124.9M-41.4%
Total debt$110.8M+16.3%
Total equity$455.1M+3.4%
Total assets$676.2M+13.5%

Cash flow

See full
Operating cash flow-$17.6M-35.2%
CapEx$7.9M+90.3%
Free cash flow-$25.4M-48.5%

Valuation & ratios

Valuation

See full
Market cap$5.39B+159%
Enterprise value$5.37B+159%
P/S13.2×+7.1×

Profitability

See full
Gross margin52.1%+5.4pp
Operating margin-33.9%-9.9pp
Net margin-19.8%-7.7pp
FCF margin-23.2%+7.0pp

Returns & leverage

See full
Return on equity-18.2%-6.3pp
Debt / equity0.2×0.0×
Current ratio2.7×-1.8×

Segments

By geography

See full
Americas$64.3M+16.5%
EMEA$37.3M+21.9%
APAC$9.1M+30.1%

By product

See full
NGS applications$57.4M+12.3%
DNA synthesis and protein solutions$53.3M+27.9%

By segment

See full
Reportable Segment$110.7M+19.3%

Competitors

Profile

Twist Bioscience is a life sciences company that has developed a proprietary silicon-based DNA synthesis platform to industrialize the engineering of biology. By miniaturizing chemical reactions on a silicon chip, the company manufactures high-quality synthetic DNA, RNA, and proteins at a significantly higher throughput and lower cost than traditional methods. Their technology serves as a foundational tool for innovation in healthcare, agriculture, industrial chemicals, and academic research.

Competitive position

Twist is a leading disruptor in DNA synthesis, utilizing a proprietary silicon-based 'writing' technology that offers superior scale and cost-efficiency compared to legacy plate-based manufacturers.

GeographiesNorth America, Europe, Asia
Customer segmentsHealthcare, Chemicals and Materials, Academic Research, Food and Agriculture
Business modelManufacturing, B2B, E-commerce, Fee-for-service, Licensing and Royalties
SuppliersSilicon chip manufacturers, Specialty chemical suppliers, Laboratory equipment providers, Enzyme and reagent suppliers
CustomersDrug discovery researchers, Clinical diagnostic labs, Agricultural biotech firms, Specialty chemical manufacturers, Academic research institutions
Listed2018
Employees919.0
CEOEmily Marine Leproust
FilingsSEC EDGAR

Questions, answered.

What is Twist Bioscience Corporation's market cap?
Twist Bioscience Corporation (TWST) has a market capitalization of $5.4B and trades on NASDAQ.
What is Twist Bioscience Corporation's revenue and profitability?
Twist Bioscience Corporation generated $409.5M in trailing twelve-month revenue with a net loss of $81.3M, representing a net margin of -19.8%. Gross margin stands at 52.1%, with free cash flow of -$95.0M. These figures are based on the Q1 2026 filing.
Who are Twist Bioscience Corporation's competitors?
Twist Bioscience Corporation's key competitors include Illumina, Inc., Integrated DNA Technologies, Inc., Agilent Technologies, Inc., and others. These companies compete in similar markets and product categories.
Who does Twist Bioscience Corporation partner with?
Twist Bioscience Corporation's notable partners include Bayer, Boehringer Ingelheim GmbH, Takeda Pharmaceutical Company Limited, and others.
Where is Twist Bioscience Corporation headquartered?
Twist Bioscience Corporation is headquartered in United States of America and employs approximately 919 people. It has been publicly traded since 2018.